General form of registration statement for all companies including face-amount certificate companies

Condensed Consolidated Interim Statements of Cash Flows

v3.6.0.2
Condensed Consolidated Interim Statements of Cash Flows - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Mar. 31, 2016
Dec. 31, 2015
Mar. 31, 2015
Operating activities              
Net (loss) income for the period $ (1,004,092) $ (2,404,644) $ 2,040,240 $ (2,464,747) $ 1,036,148 $ (5,593,906) $ (10,098,893)
Adjustment for items not affecting cash              
Depreciation 14,387 57,781 53,357 34,036 63,454 59,479 44,448
Imputed interest 0     27,677 0 0 27,677
Interest expense (4,701) 23,839 0 0 7,697 (7,459) 179
Share- based compensation expense 158,244 592,130 1,337,573 112,573 1,495,837 1,709,230 273,887
Shares issued for services 70,800 59,500 98,900 0 169,700 0 210,323
Shares to be issued for services 0     0 0 98,900 0
Change in fair value of warrant derivative liability (870,913) (2,510,388) (6,871,597) 0 (7,742,555) (484,124) 6,387,473
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities (1,636,275) (4,181,782) (3,341,527) (2,290,461) (4,969,719) (4,217,880) (3,154,906)
Changes in non-cash working capital items              
Accounts receivable   (247,359) 0        
Prepaid expenses and other receivables (43,516) 95,562 (29,798) 420,709 (73,314) (107,087) 337,451
Due from related parties (2,891) 532 2,926 0 35 6,432 0
Inventories   (120,894) (74,069)        
Accounts payable 186,153 (718,270) (275,106) 195,427 112,129 (174,229) 123,654
Accrued liabilities 458,139 (492,047) 0 34,847 183,033 (97,623) 228,840
Customer deposits   28,000 0        
Lease payable   (2,303) 0        
Deferred revenue   97,615 0        
Net cash used in operating activities (1,038,390) (5,540,946) (3,717,574) (1,639,478) (4,747,836) (4,590,387) (2,464,961)
Investing activities              
Acquisition of equipment (3,032) (9,827) (39,811) (109,316) (42,863) (80,195) (148,136)
Advances (125,153)     0 (125,153) 0 0
Provision of a loan receivable (68,750) 0 (307,459) 0 (379,908) (300,000) 0
Net cash used in investing activities (196,935) (9,827) (347,270) (109,316) (547,924) (380,195) (148,136)
Financing activity              
Proceeds from issuance of shares, net of issue costs 0 0 4,556,818 2,604,453 4,552,409 11,341,397 9,393,441
Repayment of proceeds from loans payable 0     (733,293) 0 0 (733,293)
Proceeds from the exercise of options 0     228,875 0 0 228,875
Repayment of loans from related parties 0     (111,357) 0 0 (111,357)
Provision of convertible loans   483,333 0        
Cash acquired on acquisition   266,635 0        
Net cash provided by financing activity 0 749,968 4,556,818 1,988,678 4,552,409 11,341,397 8,777,666
Effects of foreign currency exchange rate changes on cash and cash equivalents 0     (33,433) 0 36,334 (42,943)
Net (decrease) increase in cash and cash equivalents for the period (1,235,325) (4,800,805) 491,974 206,451 (743,351) 6,407,149 6,121,626
Cash and cash equivalents, beginning of period 6,617,082 5,381,757 6,125,108 3,482 6,125,108 209,933 3,482
Cash and cash equivalents, end of period 5,381,757 580,952 $ 6,617,082 209,933 5,381,757 6,617,082 6,125,108
Supplemental information:              
Issuance of shares on conversion of loans $ 0     $ 239,746 $ 0 $ 500,000 $ 500,000
Assets acquired and liabilities assumed:              
Current assets, including cash acquired of $266,635   478,843          
Equipment   59,749          
Intangible assets and goodwill   27,888,979          
Accounts payable   (241,299)          
Accrued liabilities   (361,029)          
Customer deposits   (86,487)          
Demand notes payable   (324,894)          
Promissory notes payable   (217,808)          
Bionik advance   (1,436,164)          
Non-cash consideration   $ 25,759,890